Literature DB >> 24658681

Identification of glycosylated regions in pneumococcal PspA conjugated to serotype 6B capsular polysaccharide.

Giovana Cappio Barazzone, Vittoria Pinto, Danilo Donnarumma, Martha Massako Tanizaki, Nathalie Norais, Francesco Berti.   

Abstract

Conjugate vaccines are being widely used since their introduction. Nowadays the interest in these vaccines is still growing and new antigens and conjugate chemistry are being studied and developed. Pneumococcal surface protein A (PspA) is one of the most studied pneumococcal antigens and is an important vaccine candidate. One approach to broaden the conjugate vaccine coverage could be the conjugation of the polysaccharide to a pneumococcal protein such as PspA. Previous results have shown that conjugated recombinant fragment of PspA (rPspA) not only maintained but also in some conjugates improved the induction of protective antibodies raised against the protein carrier. We describe here a characterization study to identify the domains of Streptococcus pneumoniae recombinant PspA (rPspA), from family 1 clade 1 and family 2 clade 3, involved in the conjugation with serotype 6B capsular polysaccharide.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24658681     DOI: 10.1007/s10719-014-9519-9

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  22 in total

1.  Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae.

Authors:  A H Tu; R L Fulgham; M A McCrory; D E Briles; A J Szalai
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries.

Authors:  Susan K Hollingshead; Laurence Baril; Santiago Ferro; Janice King; Pat Coan; David E Briles
Journal:  J Med Microbiol       Date:  2006-02       Impact factor: 2.472

3.  Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae.

Authors:  S K Hollingshead; R Becker; D E Briles
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae.

Authors:  M J Crain; W D Waltman; J S Turner; J Yother; D F Talkington; L S McDaniel; B M Gray; D E Briles
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

5.  Regions of PspA/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model.

Authors:  Hazeline Roche; Anders Håkansson; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

Review 6.  Streptococcus pneumoniae--a review of carriage, infection, serotype replacement and vaccination.

Authors:  Sam Mehr; Nicholas Wood
Journal:  Paediatr Respir Rev       Date:  2012-01-18       Impact factor: 2.726

7.  Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.

Authors:  Tamara Pilishvili; Catherine Lexau; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Arthur Reingold; Ann Thomas; William Schaffner; Allen S Craig; Philip J Smith; Bernard W Beall; Cynthia G Whitney; Matthew R Moore
Journal:  J Infect Dis       Date:  2010-01-01       Impact factor: 5.226

8.  Variation in the molecular weight of PspA (pneumococcal surface protein A) among Streptococcus pneumoniae.

Authors:  W D Waltman; L S McDaniel; B M Gray; D E Briles
Journal:  Microb Pathog       Date:  1990-01       Impact factor: 3.738

9.  Hydrolytic stability of pneumococcal group 6 (type 6A and 6B) capsular polysaccharides.

Authors:  G Zon; S C Szu; W Egan; J D Robbins; J B Robbins
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

10.  Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases.

Authors:  Angela Bardotti; Giovanni Averani; Francesco Berti; Stefania Berti; Valeria Carinci; Sandro D'Ascenzi; Barbara Fabbri; Sara Giannini; Aldo Giannozzi; Claudia Magagnoli; Daniela Proietti; Francesco Norelli; Rino Rappuoli; Stefano Ricci; Paolo Costantino
Journal:  Vaccine       Date:  2008-02-15       Impact factor: 3.641

View more
  1 in total

Review 1.  Protein Carriers for Glycoconjugate Vaccines: History, Selection Criteria, Characterization and New Trends.

Authors:  Francesca Micoli; Roberto Adamo; Paolo Costantino
Journal:  Molecules       Date:  2018-06-15       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.